logo
Why U.S. oil production could even go into reverse

Why U.S. oil production could even go into reverse

Axios14-04-2025
The prospect of U.S. oil production growth not just stalling but going into reverse is edging into the picture.
Why it matters: The price drop and trade policy uncertainty might spur a decline this year or next despite Trump officials' goal of boosting output.
It would be a striking example of how President Trump's trade policies hit the sector that embraces other parts of his agenda.
"At these prices, we would not be surprised to see U.S. oil output decline this year," Barclays' Amarpreet Singh said in a note Friday.
While Trump has paused big new tariffs on many countries, the baseline 10% remains, and he imposed massive levies on China.
And what happens after the 90-day pause announced last week is a mystery. So is the hit to demand growth from economic headwinds.
State of play: Even before the April 2 tariff announcement, analysts were predicting rather modest 2025 growth from world-leading levels.
Most outlooks still project a small rise. But it's looking wobbly.
The U.S. Energy Information Administration last Thursday revised its U.S. oil outlook slightly downward, now seeing production growth of 2.2% this year and 0.4% in 2026.
How it works: While shale production is rather flexible, commodity outlook changes have a delayed effect unless they're huge.
That's true even as prices are near or below what it takes to profitably drill new wells in many locations.
What they're saying: Wood Mackenzie analyst Ann-Louise Hittle noted it takes 6-9 months for a change in rig activity to affect production. Woodmac still sees modest growth this year.
"We believe even lower near-term oil prices would be needed to result in deferred well completions or shut ins to reduce 2025 Lower 48 oil supply significantly," Hittle, Woodmac's VP for oil markets, said via email.
Threat level: S&P Global Commodity Insight, even before April 2, saw just a 150,000 barrel-per-day increase in production growth from Lower 48 onshore wells this year.
If U.S. crude prices fell to $50 per barrel, S&P sees U.S. onshore production falling by over a million barrels per day over 12 months.
The U.S. benchmark WTI is trading at $62.43 Monday morning after dropping to $58-range briefly last week.
The big picture: As Axios noted recently, "drill, baby, drill" is also about setting the stage for long-term access to acreage and opportunities, not just near-term supply.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RH (RH): A Bear Case Theory
RH (RH): A Bear Case Theory

Yahoo

timea few seconds ago

  • Yahoo

RH (RH): A Bear Case Theory

We came across a bearish thesis on RH on Matt McClintock Retail/Consumer Research - M Squared Capital's Substack by Matthew McClintock. In this article, we will summarize the bulls' thesis on RH. RH's share was trading at $215.04 as of August 8th. RH's trailing and forward P/E were 50.96 and 20.12 respectively according to Yahoo Finance. Copyright: archidea / 123RF Stock Photo Restoration Hardware's (RH) 1Q25 results reinforced a bearish outlook despite a few positives, notably a 10% YoY rise in customer deposits, the strongest in three years. This contrasts with management's 2Q25 guidance for a 600 bps tariff-related revenue hit, suggesting a pull-forward in custom furniture orders ahead of price hikes. Inventory cash flow was only $18M despite aggressive discounting, and excess stock of $200–$300M at cost remains a concern for vendor relationships. Questions also arise over a 35% Outdoor discount amid claims prices weren't raised, reduced capex alongside plans to open 7–9 galleries annually, and the untested 'design compound' concept that purportedly halves build costs. Management's $500M real estate sale claim lacks clarity given limited owned stores, and prior China sourcing commitments have slipped. International expansion optimism is unconvincing; EBIT drag guidance of 180 bps for 2025 matches prior forecasts, with ongoing losses in Germany despite reported 60% demand growth off a low base, slowing growth in England's Aynho Park, and silence on RH Brussels and Sydney. Paris's planned September opening may align with Maison et Objet but could elevate SG&A. Sell-side models appear overly optimistic, assuming gross margin expansion despite permanent 30% RH Member discounts, continued clearance inventory, tariff impacts, and rising occupancy costs. SG&A forecasts also seem understated given upcoming store openings. Consensus EBIT guidance aligns with ~$10.50 EPS, but downside risk is significant, especially after a weaker-than-expected 1Q25 EPS of $0.13 vs. the bearish $0.20 scenario. The high-end EPS estimate remains $11.00, but the low-end is cut to $7.00, with visibility skewed toward downside risk. Previously, we covered a on RH by Open Insights in March 2025, highlighting its costly luxury expansion and weak cash flow. The stock depreciated about 30% since coverage as these risks materialized. The thesis still stands, given ongoing profitability concerns. Matthew McClintock shares a similar view but emphasizes inventory challenges, tariff impacts, and downside earnings risks. RH is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 46 hedge fund portfolios held RH at the end of the first quarter which was 51 in the previous quarter. While we acknowledge the potential of RH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Carvana Co. (CVNA): A Bear Case Theory
Carvana Co. (CVNA): A Bear Case Theory

Yahoo

timea few seconds ago

  • Yahoo

Carvana Co. (CVNA): A Bear Case Theory

We came across a bearish thesis on Carvana Co. on Nemonomics's Substack by Nick Nemeth. In this article, we will summarize the bulls' thesis on CVNA. Carvana Co.'s share was trading at $347.56 as of August 8th. CVNA's trailing and forward P/E were 86.46 and 69.44, respectively according to Yahoo Finance. Copyright: sonyae / 123RF Stock Photo Carvana (CVNA) has surged from near-bankruptcy to a $45+ billion market cap on strong earnings, but its valuation appears disconnected from its fundamentals. Despite being branded as an online used-car dealer, its true profit engine is consumer finance, not vehicle sales. The company originates loans, packages them, and sells them at a premium, with tiny 'metal margins' of $400–$500 per car. In 2024, it sold $6.15 billion in loans, generating $541 million in gain-on-sale income, or 26% of gross profit. Most financing flows through Bridgecrest, serving lower-credit borrowers with average FICO scores in the 567–584 range, which allows for higher rates but comes with elevated delinquency risk. Nearly 80% of customers finance through Carvana, with loans often securitized and sold, while retaining roughly 5% exposure. The business model's fortunes are tied to credit cycles—when credit weakens, loan buyers retreat, volumes collapse, and balance sheet risk rises, as seen in 2021–22. Unlike brick-and-mortar dealers, Carvana cannot fully capture lucrative service, warranty, and insurance revenue streams, which remain a major profit driver for peers trading at far lower multiples. Competitors like AutoNation, with steady profitability and broader revenue streams, are valued at a fraction of Carvana's market cap. With a price-to-book ratio near 30, investors are paying tech-like multiples for a leveraged finance operation heavily exposed to subprime auto credit and securitization markets. Without a defensible moat, Carvana's valuation hinges on sustained credit market strength, making the risk/reward profile skewed sharply if macro or credit conditions deteriorate. Previously, we covered a bullish thesis on Carvana Co. (CVNA) by Investing City in May 2025, highlighting its integrated e-commerce platform and operational efficiencies. The stock has risen about 8.5% since, as optimism outweighed macro risks. The thesis still stands on execution strength. Nick Nemeth shares a contrarian view, focusing on Carvana's reliance on subprime auto finance and credit cycles. Carvana Co. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 90 hedge fund portfolios held CVNA at the end of the first quarter which was 84 in the previous quarter. While we acknowledge the potential of CVNA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

argenx SE (ARGX): A Bull Case Theory
argenx SE (ARGX): A Bull Case Theory

Yahoo

timea few seconds ago

  • Yahoo

argenx SE (ARGX): A Bull Case Theory

We came across a bullish thesis on argenx SE on Stock Analysis Compilation. In this article, we will summarize the bulls' thesis on ARGX. argenx SE's share was trading at $661.83 as of August 8th. ARGX's trailing and forward P/E were 33.68 and 48.78 respectively according to Yahoo Finance. Likoper/ Argenx SE is a biotechnology company focused on developing Vyvgart, a leading FcRn inhibitor for autoimmune diseases, positioning it for strong long-term growth despite recent sales setbacks. The company's shares fell after first-quarter Vyvgart sales missed high investor expectations, primarily due to seasonal factors like insurance reverification and increased Medicare Part D utilization that led to higher discounts. Nevertheless, ongoing discussions with management and neurologists affirm Vyvgart's significant clinical value and its role as a key treatment option. The drug is successfully launching in key indications such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, showing solid adoption. Furthermore, the company's pipeline offers promising expansion potential, as evidenced by encouraging Phase 2 data for myositis presented at a major medical conference. This suggests Vyvgart's efficacy may extend across a broader range of autoantibody-driven autoimmune conditions, supporting a compelling long-term growth outlook. Despite short-term volatility, Argenx's core asset remains highly differentiated in the autoimmune market, with strong physician support and a growing patient base. The current share price appears to underappreciate the durable demand trajectory and the company's capacity to capture incremental indications, presenting a compelling risk/reward opportunity for investors focused on innovative biotech with sustainable growth prospects. Previously, we covered a on Argenx SE by FluentInQuality in May 2025, highlighting Vyvgart's platform approach, broad autoimmune applications, and durable revenue. Since then, the stock price has appreciated by about 5.13% by May 2025, driven by strong clinical adoption. The thesis remains valid. Stock Analysis Compilation shares a similar view but emphasizes recent seasonal sales and short-term challenges. Argenx SE is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 54 hedge fund portfolios held ARGX at the end of the first quarter which was 47 in the previous quarter. While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store